Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 311

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 10
Chunk 311
---

W. Brady and Nicholas Hemmerly. Mr. Weis is the chair of the Audit Committee. Mr. Weis qualifies as an audit committee financial expert
under SEC rules and as a financially sophisticated audit committee member under the Nasdaq Capital Market rules. Our Audit Committee
operates under a written charter that is reviewed annually. A copy of the charter is posted on the Corporate Governance
section of our website, at www.jupiterneurosciences.com.

Our
Audit Committee is authorized to:

    ●
    approve
    and retain the independent auditors to conduct the annual audit of our financial statements;

    ●
    review
    the proposed scope and results of the audit;

    ●
    review
    and pre-approve audit and non-audit fees and services;

    ●
    review
    accounting and financial controls with the independent auditors and our financial and accounting staff;

    ●
    review
    and approve transactions between us and our directors, officers and affiliates;

    ●
    recognize
    and prevent prohibited non-audit services;

    ●
    establish
    procedures for complaints received by us regarding accounting matters; and

    ●
    oversee
    internal audit functions, if any.

Compensation
Committee

We
have established a compensation committee (“Compensation Committee”), which consists of three independent directors: Nicholas
H. Hemmerly, Julie Kampf and Allison Brady. Mr. Hemmerly is the chair of the Compensation Committee. Our Compensation Committee operates
under a written charter that is reviewed annually.7 A copy of the charter is posted on the Corporate Governance section
of our website, at www.jupiterneurosciences.com.

The
Compensation Committee is authorized to:

    ●
    review
    and determine the compensation arrangements for management;

    ●
    establish
    and review general compensation policies with the objective to attract and retain superior talent, to reward individual performance
    and to achieve our financial goals;

    ●
    administer
    our incentive compensation and benefit plans and purchase plans;

    ●
    oversee
    the evaluation of the Board of Directors and management; and

    ●
    review
    the independence of any compensation advisers.

Nominating
and Corporate Governance Committee

We
have established a nominating and corporate governance committee (“Nominating and Corporate Governance Committee”), which
consists of three independent directors: Julie Kampf, Holger Weis and Nicholas H. Hemmerly. Ms. Kamp